Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: Phase 1 dose escalation trial

Keyphrases

• Adverse Events 100%
• Chemoradiation 33%
• Clinical Outcomes 33%
• Concurrent Chemoradiation 33%
• Conformal Radiation Therapy 33%
• Cost-effectiveness 33%
• Dose Level 66%
• Dose-escalation Trial 100%
• Dyspnea 33%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 33%
• Effective Therapy 33%
• Esophagitis 33%
• Fraction Size 33%
• Hypofractionated Radiation Therapy 100%
• Hypofractionation 33%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Long-term Efficacy 33%
• Long-term Safety 33%
• Lung Cancer Treatment 33%
• Maximum Tolerated Dose 66%
• Median Overall Survival 33%
• No Significant Difference 33%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Poor Performance Status 33%
• Radiation Therapy 100%
• Recurrent Non-small Cell Lung Cancer 33%
• Stereotactic Radiation 33%
• Surgical Resection 33%
• Technological Progress 33%
• Treatment Regimen 100%
• Tumoricidal Activity 33%

Medicine and Dentistry

• Adverse Event 60%
• Cancer Therapy 20%
• Chemoradiotherapy 40%
• Conformal Radiotherapy 20%
• Cost-Effectiveness Analysis 20%
• Disease 20%
• Dyspnea 20%
• Esophagitis 20%
• Hypofractionated Radiotherapy 100%
• Lung Cancer 20%
• Non Small Cell Lung Cancer 100%
• Oncology 20%
• Overall Survival 20%
• Radiation Therapy 60%
• Spine 20%
• Surgery 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 60%
• Chemoradiation Therapy 40%
• Disease 20%
• Dyspnea 20%
• Esophagitis 20%
• Lung Cancer 20%
• Maximum Tolerated Dose 40%
• Non Small Cell Lung Cancer 100%
• Overall Survival 20%